Company: GNMSF
Filing Date: 2025-02-12
Form Type: 20-F
Source: 0001558370-25-000846
Chunk: 156

Company: GENMAB A/S
Filing Date: 2025-02-12
Form: 20-F
Item: Item 16C
Chunk 156
---
 Stock Market regarding shareholder approval for certain issuances of securities under Nasdaq Listing Rule 5635. Pursuant to Danish corporate law ...  

  We do not follow the requirement of the Nasdaq Stock Market that each member of the Compensation Committee be independent as defined under Nasdaq Listing Rule 5605(a)(2). No such requirement ex...  

Table of Contents

  Committee, to be a non-independent director solely by virtue of the length of his tenure on our Board, following his election to the Board in 2003. We do not consider Dr. Pedersen’s tenure as m...  

  We do not follow the requirement of the Nasdaq Stock Market that our independent directors must have regularly scheduled meetings at which only independent directors are present. No such requir...  

ITEM 16H MINE SAFETY DISCLOSURE

Not applicable.

ITEM 16I DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

Not applicable.

ITEM 16J INSIDER TRADING POLICIES

We haveadopted two insider trading policies, one of which governs the purchase, sale, and other transactions in our securities by our Board of Directors, Executive Management and other permanent insiders and the other governs such transactions by our employees, and employees of our directly and indirectly owned subsidiaries. These policies have been reasonably designed to promote compliance with applicable insider trading laws, rules and regulations, and any listing standards applicable to us. Copies of our insider trading policies are attached as Exhibits 11.1 and 11.2 to this Annual Report.

ITEM 16K CYBERSECURITY

Overview of Cybersecurity Program and Risk Management

Safeguarding the confidentiality, integrity, and availability of systems, data and applications as well as protecting trade secrets and data privacy is an essential pillar in ensuring the business continuity of Genmab, and complying with regulatory requirements, and maintaining the trust of our patients, employees, shareholders, partners, and other stakeholders. Genmab maintains a comprehensive cybersecurity program based on the National Institute of Standards and Technology’s NIST 800 Special Publication Information Security standard (“ NIST Standard”) for managing cybersecurity activities, including formulation of global objectives of the cybersecurity program andrisk identificationand mitigation activities.